Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Liver Diseases

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 460 articles:
HTML format

Single Articles

    January 2024
  1. NAGY NS, Essawy AE, Al-Sherif SS, Ali MM, et al
    Characterization and biological applications of gonadal extract of Paracentrotus lividus collected along the Mediterranean coast of Alexandria, Egypt.
    PLoS One. 2024;19:e0296312.
    PubMed     Abstract available

  2. ORIMOLOYE HT, He D, Li T, Janzen C, et al
    Alpha-1 antitrypsin deficiency and pregnancy complications and birth outcomes: A population-based cohort study in Denmark.
    PLoS One. 2024;19:e0296434.
    PubMed     Abstract available

  3. KOGISO T, Takayanagi K, Ishizuka T, Otsuka M, et al
    Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease.
    PLoS One. 2024;19:e0296375.
    PubMed     Abstract available

  4. NAVARRO-MEZA M, Diaz-Munoz M, Cruz-Ramos JA, Trinidad Gallardo JR, et al
    Hepatocyte ballooning and steatosis in early and late gestation without liver malfunction: Effects of low protein/high carbohydrate diet.
    PLoS One. 2024;19:e0294062.
    PubMed     Abstract available

  5. GITTUS M, Moore J, Ong ACM
    Liver transplant recipients with polycystic liver disease have longer waiting times but better long-term clinical outcomes than those with liver disease due to other causes: A retrospective cross-sectional study.
    PLoS One. 2024;19:e0294717.
    PubMed     Abstract available

  6. KAI M, Hikita H, Kazuki M, Tahata Y, et al
    Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
    PLoS One. 2024;19:e0294590.
    PubMed     Abstract available

  7. QIANG B, Xu Q, Pan Y, Wang J, et al
    Shear wave elastography: A noninvasive approach for assessing acute kidney injury in critically ill patients.
    PLoS One. 2024;19:e0296411.
    PubMed     Abstract available

  8. OLSON JC, Subramanian RM
    Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0296690.
    PubMed     Abstract available

  9. SATO T, Oishi K
    Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
    PLoS One. 2024;19:e0296950.
    PubMed     Abstract available

  10. LAUE T, Junge N, Leiskau C, Mutschler F, et al
    Diminished measles immunity after paediatric liver transplantation-A retrospective, single-centre, cross-sectional analysis.
    PLoS One. 2024;19:e0296653.
    PubMed     Abstract available

  11. ELLIS P, Parekh G, Duvoix A, Watson L, et al
    Characteristics of alpha-1 antitrypsin deficiency related lung disease exacerbations using a daily symptom diary and urinary biomarkers.
    PLoS One. 2024;19:e0297125.
    PubMed     Abstract available

  12. GUHA S, Ibrahim A, Wu Q, Geng P, et al
    Machine learning-based identification of contrast-enhancement phase of computed tomography scans.
    PLoS One. 2024;19:e0294581.
    PubMed     Abstract available

  13. LIU Z, Shao Y, Duan X
    Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0298225.
    PubMed     Abstract available

  14. MATSUO M, Kanbe A, Noguchi K, Niwa A, et al
    Time-course analysis of liver and serum galectin-3 in acute liver injury after alpha-galactosylceramide injection.
    PLoS One. 2024;19:e0298284.
    PubMed     Abstract available

  15. NAIRZ J, Messner A, Kiechl SJ, Winder B, et al
    Determinants of non-alcoholic fatty liver disease in young people: Maternal, neonatal, and adolescent factors.
    PLoS One. 2024;19:e0298800.
    PubMed     Abstract available

  16. LADNER DP, Gmeiner M, Hasjim BJ, Mazumder N, et al
    Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.
    PLoS One. 2024;19:e0298887.
    PubMed     Abstract available

  17. ELGUEZABAL RODELO RG, Porchia LM, Torres-Rasgado E, Lopez-Bayghen E, et al
    Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018.
    PLoS One. 2024;19:e0298662.
    PubMed     Abstract available

  18. DUHRING S, Schuster S
    Studying mixed-species biofilms of Candida albicans and Staphylococcus aureus using evolutionary game theory.
    PLoS One. 2024;19:e0297307.
    PubMed     Abstract available

  19. CHEN Q, Sun Q, Zhang J, Li B, et al
    Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
    PLoS One. 2024;19:e0295090.
    PubMed     Abstract available

  20. STAUFFER WT, Goodman AZ, Bobardt M, Ure DR, et al
    Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
    PLoS One. 2024;19:e0298211.
    PubMed     Abstract available

  21. YANG Y, Mirzaei G
    Performance analysis of data resampling on class imbalance and classification techniques on multi-omics data for cancer classification.
    PLoS One. 2024;19:e0293607.
    PubMed     Abstract available

  22. LI YS, Xia YG, Liu YL, Jiang WR, et al
    Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study.
    PLoS One. 2024;19:e0297883.
    PubMed     Abstract available

  23. MCTEER M, Applegate D, Mesenbrink P, Ratziu V, et al
    Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
    PLoS One. 2024;19:e0299487.
    PubMed     Abstract available

  24. NAH EH, Choi YJ, Cho S, Park H, et al
    Changes in nonalcoholic fatty liver disease and M2BPGi due to lifestyle intervention in primary healthcare.
    PLoS One. 2024;19:e0298151.
    PubMed     Abstract available

  25. BUDZYNSKA A, Kubik A, Kacperski K, Pastusiak P, et al
    PET/CT and SPECT/CT imaging of 90Y hepatic radioembolization at therapeutic and diagnostic activity levels: Anthropomorphic phantom study.
    PLoS One. 2024;19:e0271711.
    PubMed     Abstract available

  26. LI H, Wang C
    MIS-Net: A deep learning-based multi-class segmentation model for CT images.
    PLoS One. 2024;19:e0299970.
    PubMed     Abstract available

  27. YAMASHITA T, Suzuki N, Motoyoshi K, Zhu W, et al
    Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan.
    PLoS One. 2024;19:e0298420.
    PubMed     Abstract available

  28. KANEKO S, Asahina Y, Murakawa M, Azuma S, et al
    Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades.
    PLoS One. 2024;19:e0297882.
    PubMed     Abstract available

  29. YANG X, Wang S, Sun C, Xia Y, et al
    Causal effect of porphyria biomarkers on alcohol-related hepatocellular carcinoma through Mendelian Randomization.
    PLoS One. 2024;19:e0299536.
    PubMed     Abstract available

  30. OKUBO T, Atsukawa M, Tsubota A, Ono H, et al
    Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease.
    PLoS One. 2024;19:e0299313.
    PubMed     Abstract available

  31. KIM A, Kang D, Choi SC, Cho J, et al
    Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score.
    PLoS One. 2024;19:e0301126.
    PubMed     Abstract available

  32. CHAISUPASAKUL P, Pekthong D, Wangteeraprasert A, Kaewkong W, et al
    Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells.
    PLoS One. 2024;19:e0300051.
    PubMed     Abstract available

  33. SRIPHOOSANAPHAN S, Pantumongkol W, Kulpeng W, Charonpongsuntorn C, et al
    Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
    PLoS One. 2024;19:e0300327.
    PubMed     Abstract available

  34. BAGER P, Bossen L, Gantzel R, Gronbaek H, et al
    High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial.
    PLoS One. 2024;19:e0301354.
    PubMed     Abstract available

  35. CAI W, Qiu T, Hu W, Fang T, et al
    Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis.
    PLoS One. 2024;19:e0299946.
    PubMed     Abstract available

  36. CHEN R, An Y, Xu M
    Prognostic difference between surgery and external radiation in patients with stage I liver cancer based on competitive risk model and conditional survival rate.
    PLoS One. 2024;19:e0298014.
    PubMed     Abstract available

  37. AZAMAR-LLAMAS D, Arenas-Martinez JS, Olivas-Martinez A, Jimenez JV, et al
    Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.
    PLoS One. 2024;19:e0301198.
    PubMed     Abstract available

  38. RAN S, Song L, Yang H, Yu J, et al
    Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-kappaB-mediated hepatocyte pyroptosis.
    PLoS One. 2024;19:e0301133.
    PubMed     Abstract available

  39. WILSON EA, Woodbury A, Williams KM, Coopersmith CM, et al
    OXIDATIVE study: A pilot prospective observational cohort study protocol examining the influence of peri-reperfusion hyperoxemia and immune dysregulation on early allograft dysfunction after orthotopic liver transplantation.
    PLoS One. 2024;19:e0301281.
    PubMed     Abstract available

  40. ZHANG H, Cheng X, Guo W, Zheng C, et al
    Metastasis patterns and prognosis in young gastric cancer patients: A propensity score?matched SEER database analysis.
    PLoS One. 2024;19:e0301834.
    PubMed     Abstract available

  41. STAUFFER WT, Bobardt M, Ure DR, Foster RT, et al
    Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
    PLoS One. 2024;19:e0301711.
    PubMed     Abstract available

  42. GABUZA K, Mabuda TI, Patel O, Khuboni N, et al
    Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD.
    PLoS One. 2024;19:e0297572.
    PubMed     Abstract available

  43. WU T, Yang H, Li J, Fang H, et al
    Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein.
    PLoS One. 2024;19:e0299920.
    PubMed     Abstract available

  44. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
    Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
    PLoS One. 2024;19:e0290632.
    PubMed     Abstract available

  45. GURUN M, Brennan P, Handjiev S, Khatib A, et al
    Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    PLoS One. 2024;19:e0299507.
    PubMed     Abstract available

  46. BAEK M, Kim M, Choi HI, Binas B, et al
    Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells.
    PLoS One. 2024;19:e0301663.
    PubMed     Abstract available

  47. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
    Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    PLoS One. 2024;19:e0301416.
    PubMed     Abstract available

  48. ADORINI L, Rigbolt K, Feigh M, Roth J, et al
    Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    PLoS One. 2024;19:e0300809.
    PubMed     Abstract available

  49. JI Z, Zhang C, Yuan J, He Q, et al
    Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
    PLoS One. 2024;19:e0298775.
    PubMed     Abstract available

  50. SUN J, Yang S, Zhang Y, Xiang W, et al
    Relationship between phthalates exposures and metabolic dysfunction-associated fatty liver disease in United States adults.
    PLoS One. 2024;19:e0301097.
    PubMed     Abstract available

  51. SMITH K, Beach D, Silva R, Balazs G, et al
    Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights.
    PLoS One. 2024;19:e0296198.
    PubMed     Abstract available

  52. LIU XH, Chen HK, Luo J, He XP, et al
    Potassium affects the association between dietary intake of vitamin C and NAFLD among adults in the United States.
    PLoS One. 2024;19:e0295986.
    PubMed     Abstract available

  53. LIU L, Zhang M, Cui N, Liu W, et al
    Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
    PLoS One. 2024;19:e0298004.
    PubMed     Abstract available

  54. LI N, Jin S, Wu J, Ji H, et al
    Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
    PLoS One. 2024;19:e0299504.
    PubMed     Abstract available

  55. LIN YH, Zhang ZJ, Zhong JQ, Wang ZY, et al
    Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    PLoS One. 2024;19:e0302155.
    PubMed     Abstract available

  56. BI CQ, Kang T, Qian YK, Kang M, et al
    Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth.
    PLoS One. 2024;19:e0299522.
    PubMed     Abstract available

  57. BENGTSSON B, Maucourant C, Sandberg JK, Bjorkstrom NK, et al
    Evaluation of mucosal-associated invariant T-cells as a potential biomarker to predict infection risk in liver cirrhosis.
    PLoS One. 2024;19:e0294695.
    PubMed     Abstract available

  58. YAMABA S, Imai Y, Sugawara K, Uchida Y, et al
    Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
    PLoS One. 2024;19:e0298770.
    PubMed     Abstract available

  59. PAN Z, Bayoumi A, Metwally M, George J, et al
    Exportin 4 DNA promoter methylation in liver fibrosis.
    PLoS One. 2024;19:e0302786.
    PubMed     Abstract available

  60. TABACU L, Swami S, Ledbetter M, Siddiqui MS, et al
    Socioeconomic status and health disparities drive differences in accelerometer-derived physical activity in fatty liver disease and significant fibrosis.
    PLoS One. 2024;19:e0301774.
    PubMed     Abstract available

  61. YUAN C, Li W, Liu J, Li J, et al
    Frailty and transplant-free survival of patients with liver cirrhosis: A meta-analysis.
    PLoS One. 2024;19:e0302836.
    PubMed     Abstract available

  62. GALIERO R, Loffredo G, Simeon V, Caturano A, et al
    Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy.
    PLoS One. 2024;19:e0296495.
    PubMed     Abstract available

  63. FUNUYET-SALAS J, Martin-Rodriguez A, Perez-San-Gregorio MA, Vale L, et al
    Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.
    PLoS One. 2024;19:e0300362.
    PubMed     Abstract available

  64. VATSYAYAN A, Kumar M, Saikia BJ, Scaria V, et al
    WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease.
    PLoS One. 2024;19:e0303787.
    PubMed     Abstract available

  65. OSAWA Y, Kawai H, Nakashima K, Nakaseko Y, et al
    Sphingosine-1-phosphate promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.
    PLoS One. 2024;19:e0303296.
    PubMed     Abstract available

    January 2023
  66. YANG CK, Huang CH, Hu CH, Fang JH, et al
    Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.
    PLoS One. 2023;18:e0280023.
    PubMed     Abstract available

  67. KARLSSON M, Simonsson C, Dahlstrom N, Cedersund G, et al
    Mathematical models for biomarker calculation of drug-induced liver injury in humans and experimental models based on gadoxetate enhanced magnetic resonance imaging.
    PLoS One. 2023;18:e0279168.
    PubMed     Abstract available

  68. KASZTELAN-SZCZERBINSKA B, Zygo B, Rycyk-Bojarzynska A, Surdacka A, et al
    Blood concentrations of mediators released from activated neutrophils are related to the severity of alcohol-induced liver damage.
    PLoS One. 2023;18:e0280068.
    PubMed     Abstract available

  69. GAUGAIN L, Cawston H, Dubois de Gennes C, Sanchez Alvares J, et al
    Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France.
    PLoS One. 2023;18:e0280442.
    PubMed     Abstract available

  70. ZHENG Z, Hu Y, Ren Y, Mo G, et al
    Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study.
    PLoS One. 2023;18:e0267809.
    PubMed     Abstract available

  71. MAESAKA K, Sakamori R, Yamada R, Doi A, et al
    Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    PLoS One. 2023;18:e0281459.
    PubMed     Abstract available

  72. CUI S, Chen Y, Guo Y, Wang X, et al
    Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration/ invasion by indirectly regulating SPRY2.
    PLoS One. 2023;18:e0281536.
    PubMed     Abstract available

  73. SANT ANNA FM, Araujo-Pereira M, Schmaltz CAS, Arriaga MB, et al
    Impact of adverse drug reactions on the outcomes of tuberculosis treatment.
    PLoS One. 2023;18:e0269765.
    PubMed     Abstract available

  74. DARMADI D, Pakpahan C, Ruslie RH, Amanda B, et al
    The sex life of male patients with cirrhosis and its organic factors: What we have got so far?
    PLoS One. 2023;18:e0280915.
    PubMed     Abstract available

  75. SCHAMBECK JPL, Forte GC, Goncalves LM, Stuker G, et al
    Diagnostic accuracy of magnetic resonance elastography and point-shear wave elastography for significant hepatic fibrosis screening: Systematic review and meta-analysis.
    PLoS One. 2023;18:e0271572.
    PubMed     Abstract available

  76. GAWRIEH S, Corey KE, Lake JE, Samala N, et al
    Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virus.
    PLoS One. 2023;18:e0279685.
    PubMed     Abstract available

  77. LI WF, Liu YW, Wang CC, Yong CC, et al
    Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of
    PLoS One. 2023;18:e0281154.
    PubMed     Abstract available

  78. O'CONNELL MB, Bendtsen F, Norholm V, Brodsgaard A, et al
    Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review.
    PLoS One. 2023;18:e0278545.
    PubMed     Abstract available

  79. SOREMEKUN C, Machipisa T, Soremekun O, Pirie F, et al
    Multivariate GWAS analysis reveals loci associated with liver functions in continental African populations.
    PLoS One. 2023;18:e0280344.
    PubMed     Abstract available

  80. PENG YL, Wang LX, Li MY, Liu LP, et al
    Construction and validation of a prognostic signature based on necroptosis-related genes in hepatocellular carcinoma.
    PLoS One. 2023;18:e0279744.
    PubMed     Abstract available

  81. DALBENI A, Mantovani A, Zoncape M, Cattazzo F, et al
    The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study.
    PLoS One. 2023;18:e0281813.
    PubMed     Abstract available

  82. THRIFT AP, Kanwal F, Liu Y, Khaderi S, et al
    Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score.
    PLoS One. 2023;18:e0282309.
    PubMed     Abstract available

  83. ZHOU T, Wei H, Wang J
    Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.
    PLoS One. 2023;18:e0279431.
    PubMed     Abstract available

  84. XU Z, Qi G, Liu X, Li Z, et al
    Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014-2021.
    PLoS One. 2023;18:e0281983.
    PubMed     Abstract available

  85. VOROS K, Markus B, Atzel K, Szalay F, et al
    Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease.
    PLoS One. 2023;18:e0282801.
    PubMed     Abstract available

  86. DAVWAR PM, Okeke E, Duguru M, Nyam D, et al
    Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV.
    PLoS One. 2023;18:e0282539.
    PubMed     Abstract available

  87. LESER C, Dorffner G, Marhold M, Rutter A, et al
    Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study.
    PLoS One. 2023;18:e0278454.
    PubMed     Abstract available

  88. GE C, Ma C, Cui J, Dong X, et al
    Rapamycin suppresses inflammation and increases the interaction between p65 and IkappaBalpha in rapamycin-induced fatty livers.
    PLoS One. 2023;18:e0281888.
    PubMed     Abstract available

  89. MEYER EL, Mesenbrink P, Di Prospero NA, Pericas JM, et al
    Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.
    PLoS One. 2023;18:e0281674.
    PubMed     Abstract available

  90. SAMAYOA-REYES G, Flaherty SM, Wickham KS, Viera-Morilla S, et al
    Development of an ectopic huLiver model for Plasmodium liver stage infection.
    PLoS One. 2023;18:e0279144.
    PubMed     Abstract available

  91. LI QG, Liu ZG, Dong G, Sun Y, et al
    Nanosecond pulsed electric field ablates rabbit VX2 liver tumors in a non-thermal manner.
    PLoS One. 2023;18:e0273754.
    PubMed     Abstract available

  92. WAESPE N, Mlakar SJ, Dupanloup I, Rezgui MA, et al
    A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome.
    PLoS One. 2023;18:e0281892.
    PubMed     Abstract available

  93. AHMADI A, Roy S, Mehrabbeik M, Ghosh D, et al
    The dynamics of a duopoly Stackelberg game with marginal costs among heterogeneous players.
    PLoS One. 2023;18:e0283757.
    PubMed     Abstract available

  94. GALMEN K, Jakobsson JG, Perchiazzi G, Freedman J, et al
    Quantitative assessment of atelectasis formation under high frequency jet ventilation during liver tumour ablation-A computer tomography study.
    PLoS One. 2023;18:e0282724.
    PubMed     Abstract available

  95. GUL F, Parvaiz N, Azam SS
    Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations.
    PLoS One. 2023;18:e0283743.
    PubMed     Abstract available

  96. YE Y, Lui VCH, Babu RO, Wu Z, et al
    Identification of cancer-related genes FGFR2 and CEBPB in choledochal cyst via RNA sequencing of patient-derived liver organoids.
    PLoS One. 2023;18:e0283737.
    PubMed     Abstract available

  97. BALCAR L, Bauer D, Pomej K, Meischl T, et al
    Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients.
    PLoS One. 2023;18:e0282680.
    PubMed     Abstract available

  98. TBEILEH N, Timmerman L, Mattis AN, Toriguchi K, et al
    Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    PLoS One. 2023;18:e0271354.
    PubMed     Abstract available

  99. CUSHMAN M, Callas PW, Alexander KS, Wadley V, et al
    Nonalcoholic fatty liver disease and cognitive impairment: A prospective cohort study.
    PLoS One. 2023;18:e0282633.
    PubMed     Abstract available

  100. WANG L, Peng Y, Qin S, Wan X, et al
    First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    PLoS One. 2023;18:e0279786.
    PubMed     Abstract available

  101. SOHAIL J, Zubair M, Hussain K, Faisal M, et al
    Pharmacological activities of Artemisia absinthium and control of hepatic cancer by expression regulation of TGFbeta1 and MYC genes.
    PLoS One. 2023;18:e0284244.
    PubMed     Abstract available

  102. JANNONE G, de Magnee C, Tambucci R, Evraerts J, et al
    Premature senescence of the liver in Alagille patients.
    PLoS One. 2023;18:e0285019.
    PubMed     Abstract available

  103. KAIDA T, Fujiyama Y, Soeno T, Yokota M, et al
    Less demand on stem cell marker-positive cancer cells may characterize metastasis of colon cancer.
    PLoS One. 2023;18:e0277395.
    PubMed     Abstract available

  104. BUYCO DG, Dempsey JL, Scorletti E, Jeon S, et al
    Concomitant western diet and chronic-binge alcohol dysregulate hepatic metabolism.
    PLoS One. 2023;18:e0281954.
    PubMed     Abstract available

  105. BEG MA, Rehman A, Rehman L, Ullah R, et al
    Characterization of Monoamine Oxidase-A in tropical liver fluke, Fasciola gigantica.
    PLoS One. 2023;18:e0284991.
    PubMed     Abstract available

  106. NIITSU Y, Komiya C, Takeuchi A, Hara K, et al
    Increased serum extracellular vesicle miR-144-3p and miR-486a-3p in a mouse model of adipose tissue regeneration promote hepatocyte proliferation by targeting Txnip.
    PLoS One. 2023;18:e0284989.
    PubMed     Abstract available

  107. ISLAM SMT, Palanisamy AP, Chedister GR, Schmidt MG, et al
    Unsaturated or saturated dietary fat-mediated steatosis impairs hepatic regeneration following partial hepatectomy in mice.
    PLoS One. 2023;18:e0284428.
    PubMed     Abstract available

  108. DU R, Tang XY, Yang C, Gao WH, et al
    Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: A cross-sectional study.
    PLoS One. 2023;18:e0284859.
    PubMed     Abstract available

  109. LUO J, Zheng Z, Yu R
    Analysis of medical malpractice liability disputes related to novel antineoplastic drugs and research on risk prevention and control strategies.
    PLoS One. 2023;18:e0286623.
    PubMed     Abstract available

  110. GRAHAM DS, Liu G, Arasteh A, Yin XM, et al
    Ability of high fat diet to induce liver pathology correlates with the level of linoleic acid and Vitamin E in the diet.
    PLoS One. 2023;18:e0286726.
    PubMed     Abstract available

  111. LI X, Lu Y, Liang X, Zhou X, et al
    A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    PLoS One. 2023;18:e0286257.
    PubMed     Abstract available

  112. HU J, Xie C, Xu S, Pu Q, et al
    Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma.
    PLoS One. 2023;18:e0286017.
    PubMed     Abstract available

  113. HE S, Zhang Y, Tan C, Tan W, et al
    Inverted U-shaped relationships between bone mineral density and VCTE-quantified degree of hepatic steatosis in adolescents: Evidence from the NHANES.
    PLoS One. 2023;18:e0286688.
    PubMed     Abstract available

  114. RAY EM, Teal RW, Carda-Auten J, Coffman E, et al
    Qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina.
    PLoS One. 2023;18:e0287338.
    PubMed     Abstract available

  115. FRANZ C, Wuehrl M, Hartmann S, Klupp F, et al
    Long non-coding RNAs CCAT1 and CCAT2 in colorectal liver metastases are tumor-suppressive via MYC interaction and might predict patient outcomes.
    PLoS One. 2023;18:e0286486.
    PubMed     Abstract available

  116. LIU Y, Shen B, Huang T, Wang J, et al
    Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.
    PLoS One. 2023;18:e0288013.
    PubMed     Abstract available

  117. SINN DH, Kang D, Guallar E, Choi SC, et al
    Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study.
    PLoS One. 2023;18:e0288820.
    PubMed     Abstract available

  118. CHOI J, Joe H, Oh JE, Cho YJ, et al
    The correlation between NAFLD and serum uric acid to serum creatinine ratio.
    PLoS One. 2023;18:e0288666.
    PubMed     Abstract available

  119. MITROVIC N, Sabanovic M, Vujovic A, Jovanovic J, et al
    Influence of chronic liver diseases on the course and outcome of COVID-19.
    PLoS One. 2023;18:e0288350.
    PubMed     Abstract available

  120. BRADSHAW D, Abramowicz I, Bremner S, Verma S, et al
    Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0288598.
    PubMed     Abstract available

  121. FITZPATRICK E, Filippi C, Jagadisan B, Shivapatham D, et al
    Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)-An open-label, single-arm Simon's two stage phase 1 study pr
    PLoS One. 2023;18:e0288185.
    PubMed     Abstract available

  122. NEROLDOVA M, Ciara E, Slatinska J, Frankova S, et al
    Exome sequencing reveals IFT172 variants in patients with non-syndromic cholestatic liver disease.
    PLoS One. 2023;18:e0288907.
    PubMed     Abstract available

  123. ZHANG K, Hu J, Zhao Z
    Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2.
    PLoS One. 2023;18:e0289024.
    PubMed     Abstract available

  124. LIU XF, Lu JJ, Li Y, Yang XY, et al
    The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study.
    PLoS One. 2023;18:e0289688.
    PubMed     Abstract available

  125. SUZUKI-KEMURIYAMA N, Abe A, Nakane S, Yuki M, et al
    Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
    PLoS One. 2023;18:e0287657.
    PubMed     Abstract available

  126. PENG YL, Dong YF, Guo LL, Li MY, et al
    Identification and validation of a m7G-related lncRNA signature for predicting the prognosis and therapy response in hepatocellular carcinoma.
    PLoS One. 2023;18:e0289552.
    PubMed     Abstract available

  127. KHANMOHAMMADI S, Behnoush AH, Akhlaghpoor S
    Survival outcomes and quality of life after percutaneous cryoablation for liver metastasis: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0289975.
    PubMed     Abstract available

  128. LIAO Z, Wang Z, Su C, Pei Y, et al
    Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0290164.
    PubMed     Abstract available

  129. MOEUNG S, Chassagne F, Goyet S, Nhoeung S, et al
    Traditional medicine consumption in postpartum for HBV-infected women enrolled in the ANRS 12345 TA PROHM study in Cambodia.
    PLoS One. 2023;18:e0288389.
    PubMed     Abstract available

  130. JIANG W, Shi K, Zhang L, Jiang W, et al
    Modelling of pricing, crashing, and coordination strategies of prefabricated construction supply Chain with power structure.
    PLoS One. 2023;18:e0289630.
    PubMed     Abstract available

  131. XU J, Cao J, Kumar S, Wu S, et al
    Optimal government and manufacturer incentive contracts for green production with asymmetric information.
    PLoS One. 2023;18:e0289639.
    PubMed     Abstract available

  132. PESTI-ASBOTH G, Szilagyi E, Birone Molnar P, Olah J, et al
    Monitoring physiological processes of fast-growing broilers during the whole life cycle: Changes of redox-homeostasis effected to trassulfuration pathway predicting the development of non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0290310.
    PubMed     Abstract available

  133. SHEN X, Wu S, Yang Z, Zhu C, et al
    Establishment of an endoplasmic reticulum stress-associated lncRNAs model to predict prognosis and immunological characteristics in hepatocellular carcinoma.
    PLoS One. 2023;18:e0287724.
    PubMed     Abstract available

  134. NIU X, Fu Y, Feng L, Xie M, et al
    Upper-critical solution temperature (UCST) polymer functionalized nanomedicine for controlled drug release and hypoxia alleviation in hepatocellular carcinoma therapy.
    PLoS One. 2023;18:e0290237.
    PubMed     Abstract available

  135. LIAO C, Liang X, Zhang X, Li Y, et al
    The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0289616.
    PubMed     Abstract available

  136. SEO HY, Lee SH, Park JY, Han E, et al
    Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver.
    PLoS One. 2023;18:e0290532.
    PubMed     Abstract available

  137. HE Z, Shen X, Wang B, Xu L, et al
    CT radiomics for noninvasively predicting NQO1 expression levels in hepatocellular carcinoma.
    PLoS One. 2023;18:e0290900.
    PubMed     Abstract available

  138. HEERKENS L, van Kleef LA, de Knegt RJ, Voortman T, et al
    Fatty Liver Index and mortality after myocardial infarction: A prospective analysis in the Alpha Omega Cohort.
    PLoS One. 2023;18:e0287467.
    PubMed     Abstract available

  139. FENG Q, Lu H, Wu L
    Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.
    PLoS One. 2023;18:e0291645.
    PubMed     Abstract available

  140. SCHMIDT U, Uluca B, Vokic I, Malik B, et al
    Inducible overexpression of a FAM3C/ILEI transgene has pleiotropic effects with shortened life span, liver fibrosis and anemia in mice.
    PLoS One. 2023;18:e0286256.
    PubMed     Abstract available

  141. TITHI TI, Tahsin MR, Anjum J, Zaman TS, et al
    An in vivo and in silico evaluation of the hepatoprotective potential of Gynura procumbens: A promising agent for combating hepatotoxicity.
    PLoS One. 2023;18:e0291125.
    PubMed     Abstract available

  142. HINTZEN KFH, Eussen MMM, Neutel C, Bouvy ND, et al
    A systematic review on the detection of volatile organic compounds in exhaled breath in experimental animals in the context of gastrointestinal and hepatic diseases.
    PLoS One. 2023;18:e0291636.
    PubMed     Abstract available

  143. NAGAI K, Tamura M, Murayama R, Fukuno S, et al
    Development of multi-drug resistance to anticancer drugs in HepG2 cells due to MRP2 upregulation on exposure to menthol.
    PLoS One. 2023;18:e0291822.
    PubMed     Abstract available

  144. BEER S, Babel J, Martin N, Blank V, et al
    Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
    PLoS One. 2023;18:e0286882.
    PubMed     Abstract available

  145. HUANG Q, Guo J, Zhao H, Zheng Y, et al
    The associations of alcoholic liver disease and nonalcoholic fatty liver disease with bone mineral density and the mediation of serum 25-Hydroxyvitamin D: A bidirectional and two-step Mendelian randomization.
    PLoS One. 2023;18:e0292881.
    PubMed     Abstract available

  146. CHAKRABARTY D, Wang K, Roy G, Bhojgaria A, et al
    Constructing training set using distance between learnt graphical models of time series data on patient physiology, to predict disease scores.
    PLoS One. 2023;18:e0292404.
    PubMed     Abstract available

  147. PHAM HN, Pham L, Sato K
    Bioinformatic analysis identified novel candidate genes with the potentials for diagnostic blood testing of primary biliary cholangitis.
    PLoS One. 2023;18:e0292998.
    PubMed     Abstract available

  148. TAN Z, Zhang J, Xu L, Wang H, et al
    Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0290644.
    PubMed     Abstract available

  149. CHACON C, Arteaga I, Martinez-Escude A, Ruiz Rojano I, et al
    Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol.
    PLoS One. 2023;18:e0286586.
    PubMed     Abstract available

  150. NAGAKAWA K, Hidaka M, Hara T, Matsushima H, et al
    Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis.
    PLoS One. 2023;18:e0293593.
    PubMed     Abstract available

  151. ANTWI MB, Dumitriu G, Simon-Santamaria J, Romano JS, et al
    Liver sinusoidal endothelial cells show reduced scavenger function and downregulation of Fc gamma receptor IIb, yet maintain a preserved fenestration in the Glmpgt/gt mouse model of slowly progressing liver fibrosis.
    PLoS One. 2023;18:e0293526.
    PubMed     Abstract available

  152. CHIHARA K, Okada K, Uchida F, Miura I, et al
    Macrophage specific restoration of the Nrf2 gene in whole-body knockout mice ameliorates steatohepatitis induced by lipopolysaccharide from Porphyromonas gingivalis through enhanced hepatic clearance.
    PLoS One. 2023;18:e0291880.
    PubMed     Abstract available

  153. RIENECK K, Rasmussen KK, Schoof EM, Clausen FB, et al
    Hunting for the elusive target antigen in gestational alloimmune liver disease (GALD).
    PLoS One. 2023;18:e0286432.
    PubMed     Abstract available

  154. SPOONER MH, Garcia-Jaramillo M, Apperson KD, Lohr CV, et al
    Time course of western diet (WD) induced nonalcoholic steatohepatitis (NASH) in female and male Ldlr-/- mice.
    PLoS One. 2023;18:e0292432.
    PubMed     Abstract available

  155. PARK SS, Mai M, Ploszaj M, Cai H, et al
    Type 1 diabetes contributes to combined pulmonary fibrosis and emphysema in male alpha 1 antitrypsin deficient mice.
    PLoS One. 2023;18:e0291948.
    PubMed     Abstract available

  156. CABARCAS-PETROSKI S, Olshefsky G, Schramm L
    MAF1 is a predictive biomarker in HER2 positive breast cancer.
    PLoS One. 2023;18:e0291549.
    PubMed     Abstract available

  157. ARSHAD U, Zenobi MG, Tribulo P, Staples CR, et al
    Dose-dependent effects of rumen-protected choline on hepatic metabolism during induction of fatty liver in dry pregnant dairy cows.
    PLoS One. 2023;18:e0290562.
    PubMed     Abstract available

  158. ZOU H, Xue Y, Chen X, Lai Y, et al
    Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.
    PLoS One. 2023;18:e0292239.
    PubMed     Abstract available

  159. HAYASHI H, Shimizu A, Kubota K, Notake T, et al
    Impact of sarcopenic obesity on post-hepatectomy bile leakage for hepatocellular carcinoma.
    PLoS One. 2023;18:e0286353.
    PubMed     Abstract available

  160. YANG H, Meng L, Xin S, Chang C, et al
    Non-linear association between aspartate aminotransferase to alanine aminotransferase ratio and mortality in critically ill older patients: A retrospective cohort study.
    PLoS One. 2023;18:e0293749.
    PubMed     Abstract available

  161. MOON JJ, Hong SK, Kim YC, Hong SY, et al
    Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes.
    PLoS One. 2023;18:e0293844.
    PubMed     Abstract available

  162. OEHM AW, Zablotski Y, Hoedemaker M, Campe A, et al
    Associations of production characteristics with the on-farm presence of Fasciola hepatica in dairy cows vary across production levels and indicate differences between breeds.
    PLoS One. 2023;18:e0294601.
    PubMed     Abstract available

  163. YEN YH, Kuo FY, Eng HL, Liu YW, et al
    Tumor necrosis as a predictor of early tumor recurrence after resection in patients with hepatoma.
    PLoS One. 2023;18:e0292144.
    PubMed     Abstract available

  164. SONG W, Yan X, Zhai Y, Ren J, et al
    Probiotics attenuate valproate-induced liver steatosis and oxidative stress in mice.
    PLoS One. 2023;18:e0294363.
    PubMed     Abstract available

  165. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    PubMed     Abstract available

  166. LIU K, Hu S, Qiu L, Wang M, et al
    Nrf1 is not a direct target gene of SREBP1, albeit both are integrated into the rapamycin-responsive regulatory network in human hepatoma cells.
    PLoS One. 2023;18:e0294508.
    PubMed     Abstract available

  167. JUNG C, Park S, Kim H
    Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    PLoS One. 2023;18:e0294423.
    PubMed     Abstract available

  168. TATEAI Y, Kawakami K, Teramae M, Fukuda N, et al
    Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.
    PLoS One. 2023;18:e0294320.
    PubMed     Abstract available

  169. CHO BS, Fligor SC, Fell GL, Secor JD, et al
    A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.
    PLoS One. 2023;18:e0295244.
    PubMed     Abstract available

  170. QIU B, Liang JX, Romero Gomez M
    The efficacy and safety of granulocyte colony-stimulating factor in the treatment of acute-on-chronic liver failure: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0294818.
    PubMed     Abstract available

  171. BITTER EE, Skidmore J, Allen CI, Erickson RI, et al
    TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.
    PLoS One. 2023;18:e0293128.
    PubMed     Abstract available

  172. IIZASA S, Nagao K, Tsuge K, Nagano Y, et al
    Identification of genes regulated by lipids from seaweed Susabinori (Pyropia yezoensis) involved in the improvement of hepatic steatosis: Insights from RNA-Seq analysis in obese db/db mice.
    PLoS One. 2023;18:e0295591.
    PubMed     Abstract available

  173. OEHM AW, Zablotski Y, Campe A, Hoedemaker M, et al
    Random forest classification as a tool in epidemiological modelling: Identification of farm-specific characteristics relevant for the occurrence of Fasciola hepatica on German dairy farms.
    PLoS One. 2023;18:e0296093.
    PubMed     Abstract available

  174. MOUNIKA N, Yadav A, Kamboj P, Banerjee SK, et al
    Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH).
    PLoS One. 2023;18:e0295839.
    PubMed     Abstract available

  175. GUO Y, Chen Y, Zhang Y, Xu M, et al
    Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis.
    PLoS One. 2023;18:e0295323.
    PubMed     Abstract available

  176. PORUKALA M, Vinod PK
    Gene expression signatures of stepwise progression of Hepatocellular Carcinoma.
    PLoS One. 2023;18:e0296454.
    PubMed     Abstract available

  177. PELOSO A, Lacotte S, Gex Q, Slits F, et al
    Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models.
    PLoS One. 2023;18:e0296265.
    PubMed     Abstract available

    January 2022
  178. KONDO T, Koroki K, Kanzaki H, Kobayashi K, et al
    Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0261619.
    PubMed     Abstract available

  179. THOMAS KL, Root CL, Peterson JM
    Transgenic overexpression of CTRP3 does not prevent alcohol induced hepatic steatosis in female mice.
    PLoS One. 2022;17:e0258557.
    PubMed     Abstract available

  180. DRESSEL-BOHM S, Richter H, Kircher PR, Del Chicca F, et al
    Hypoattenuating periportal halo on CT in a patient population can occur in presence of a variety of diseases.
    PLoS One. 2022;17:e0260436.
    PubMed     Abstract available

  181. KIM KE, Sinn DH, Choi MS, Kim H, et al
    Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment.
    PLoS One. 2022;17:e0262750.
    PubMed     Abstract available

  182. ABDALLAH HMI, El Awdan SA, Abdel-Rahman RF, Farrag ARH, et al
    1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-beta1, FSCN1, Vimentin, VEGF, and MMP-9.
    PLoS One. 2022;17:e0258998.
    PubMed     Abstract available

  183. DU Y, Cortez A, Josefsson A, Zarisfi M, et al
    Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.
    PLoS One. 2022;17:e0261982.
    PubMed     Abstract available

  184. LIU X, Taylor SA, Gromer KD, Zhang D, et al
    Mechanisms of liver injury in high fat sugar diet fed mice that lack hepatocyte X-box binding protein 1.
    PLoS One. 2022;17:e0261789.
    PubMed     Abstract available

  185. MEIJER TS, Dieters JHN, de Leede EM, de Geus-Oei LF, et al
    Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer.
    PLoS One. 2022;17:e0261939.
    PubMed     Abstract available

  186. RADFORD-SMITH DE, Patel PJ, Irvine KM, Russell A, et al
    Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism.
    PLoS One. 2022;17:e0261555.
    PubMed     Abstract available

  187. BRAUNWARTH E, Schullian P, Kummann M, Reider S, et al
    Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-Stereotactic radiofrequency ablation as a valuable addition to hepatic resection.
    PLoS One. 2022;17:e0261136.
    PubMed     Abstract available

  188. MIZUNO H, Sekine A, Suwabe T, Ikuma D, et al
    Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
    PLoS One. 2022;17:e0264065.
    PubMed     Abstract available

  189. KIM SS, Kycia I, Karski M, Ma RK, et al
    DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
    PLoS One. 2022;17:e0263829.
    PubMed     Abstract available

  190. SANSILVESTRI MOREL P, Duvivier V, Bertin F, Provost N, et al
    Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.
    PLoS One. 2022;17:e0263828.
    PubMed     Abstract available

  191. ASADULLAH M, Shivashankar R, Shalimar, Kandasamy D, et al
    Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population.
    PLoS One. 2022;17:e0263768.
    PubMed     Abstract available

  192. YAN J, Huang QY, Huang YJ, Wang CS, et al
    SPATS2 is positively activated by long noncoding RNA SNHG5 via regulating DNMT3a expression to promote hepatocellular carcinoma progression.
    PLoS One. 2022;17:e0262262.
    PubMed     Abstract available

  193. ROH JH, Lee H, Yun-Jeong B, Park CS, et al
    A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults.
    PLoS One. 2022;17:e0262715.
    PubMed     Abstract available

  194. KANMANI P, Kim H
    Probiotics counteract the expression of hepatic profibrotic genes via the attenuation of TGF-beta/SMAD signaling and autophagy in hepatic stellate cells.
    PLoS One. 2022;17:e0262767.
    PubMed     Abstract available

  195. YAMAOKA K, Kodama K, Kawaoka T, Kosaka M, et al
    The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
    PLoS One. 2022;17:e0262675.
    PubMed     Abstract available

  196. LAI HF, Chau IY, Lei HJ, Chou SC, et al
    Postoperative fever after liver resection: Incidence, risk factors, and characteristics associated with febrile infectious complication.
    PLoS One. 2022;17:e0262113.
    PubMed     Abstract available

  197. MATSUSHIMA-NISHIWAKI R, Yamada N, Hattori Y, Hosokawa Y, et al
    SERMs (selective estrogen receptor modulator), acting as estrogen receptor beta agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-alpha-induced migration via specific inhibition of AKT signaling pathway.
    PLoS One. 2022;17:e0262485.
    PubMed     Abstract available

  198. FERNANDEZ T, Vinuela M, Vidal C, Barrera F, et al
    Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263931.
    PubMed     Abstract available

  199. STOFFERS P, Guckenbiehl S, Welker MW, Zeuzem S, et al
    Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation.
    PLoS One. 2022;17:e0263989.
    PubMed     Abstract available

  200. SUWIMOL S, Pisit T, Anchalee A, Narisorn K, et al
    Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand.
    PLoS One. 2022;17:e0263826.
    PubMed     Abstract available

  201. RATNASARI N, Lestari P, Renovaldi D, Raditya Ningsih J, et al
    Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.
    PLoS One. 2022;17:e0263298.
    PubMed     Abstract available

  202. LIU L, Fu Q, Li T, Shao K, et al
    Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency.
    PLoS One. 2022;17:e0262855.
    PubMed     Abstract available

  203. YOKOYAMA K, Sakamaki A, Takahashi K, Naruse T, et al
    Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.
    PLoS One. 2022;17:e0264459.
    PubMed     Abstract available

  204. MORISHITA A, Tadokoro T, Fujihara S, Iwama H, et al
    Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
    PLoS One. 2022;17:e0261310.
    PubMed     Abstract available

  205. ARNEY J, Gray C, Clark JA, Smith D, et al
    Prognosis conversations in advanced liver disease: A qualitative interview study with health professionals and patients.
    PLoS One. 2022;17:e0263874.
    PubMed     Abstract available

  206. MILES LF, Couture EJ, Potes C, Makar T, et al
    Preliminary experience with continuous right ventricular pressure and transesophageal echocardiography monitoring in orthotopic liver transplantation.
    PLoS One. 2022;17:e0263386.
    PubMed     Abstract available

  207. SAKAMAKI A, Takamura M, Sakai N, Watanabe Y, et al
    Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis.
    PLoS One. 2022;17:e0263464.
    PubMed     Abstract available

  208. LE BOUTILLIER C, Snowdon C, Patel V, McPhail M, et al
    Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices.
    PLoS One. 2022;17:e0263288.
    PubMed     Abstract available

  209. SARMADI N, Poustchi H, Ali Yari F, Radmard AR, et al
    Anti-inflammatory function of apolipoprotein B-depleted plasma is impaired in non-alcoholic fatty liver disease.
    PLoS One. 2022;17:e0266227.
    PubMed     Abstract available

  210. KADDU-MULINDWA D, von Martial M, Thiel-Bodenstaff A, Lesan V, et al
    Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization.
    PLoS One. 2022;17:e0266069.
    PubMed     Abstract available

  211. KIM D, Kim JH, Ko DR, Min IK, et al
    Usefulness of contrast-enhanced multi-detector computed tomography in identifying upper gastrointestinal bleeding: A retrospective study of patients admitted to the emergency department.
    PLoS One. 2022;17:e0266622.
    PubMed     Abstract available

  212. ANENI EC, Saeed GJ, Bittencourt MS, Cainzos-Achirica M, et al
    Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals.
    PLoS One. 2022;17:e0266505.
    PubMed     Abstract available

  213. CAROL M, Perez-Guasch M, Sola E, Cervera M, et al
    Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life.
    PLoS One. 2022;17:e0265153.
    PubMed     Abstract available

  214. HAYASHI R, Kogiso T, Kikuchi N, Yamamoto K, et al
    Portopulmonary hypertension and the risk of high right ventricular systolic pressure in liver transplant candidates.
    PLoS One. 2022;17:e0267125.
    PubMed     Abstract available

  215. WORETA TA, Van Natta ML, Lazo M, Krishnan A, et al
    Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    PLoS One. 2022;17:e0266859.
    PubMed     Abstract available

  216. SALMAN M, Kamel MA, El-Nabi SEH, Ismail AHA, et al
    The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis.
    PLoS One. 2022;17:e0265455.
    PubMed     Abstract available

  217. GHOSH A, Sarmah P, Patel H, Mukerjee N, et al
    Nonlinear molecular dynamics of quercetin in Gynocardia odorata and Diospyros malabarica fruits: Its mechanistic role in hepatoprotection.
    PLoS One. 2022;17:e0263917.
    PubMed     Abstract available

  218. NAKAZAWA M, Imai Y, Sugawara K, Uchida Y, et al
    Long-term outcomes of patients with cirrhosis presenting with bleeding gastric varices.
    PLoS One. 2022;17:e0264359.
    PubMed     Abstract available

  219. FU J, Gao Y, Shi L
    Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0267647.
    PubMed     Abstract available

  220. ISHII M, Itano O, Morinaga J, Shirakawa H, et al
    Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    PLoS One. 2022;17:e0266707.
    PubMed     Abstract available

  221. GAIRING SJ, Galle PR, Schattenberg JM, Kostev K, et al
    Portal vein thrombosis is associated with an increased risk of bone fractures.
    PLoS One. 2022;17:e0267535.
    PubMed     Abstract available

  222. NGUYEN TB, Do DN, Nguyen TTP, Nguyen TL, et al
    Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.
    PLoS One. 2022;17:e0267358.
    PubMed     Abstract available

  223. CHEN PC, Lee YC, Su YC, Lee CH, et al
    Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan.
    PLoS One. 2022;17:e0266960.
    PubMed     Abstract available

  224. BAEK M, Chai JC, Choi HI, Yoo E, et al
    Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells.
    PLoS One. 2022;17:e0266966.
    PubMed     Abstract available

  225. GOLD LC, Macpherson I, Nobes JH, Dow E, et al
    Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy.
    PLoS One. 2022;17:e0267124.
    PubMed     Abstract available

  226. HU S, Zhang J, Guo G, Zhang L, et al
    Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.
    PLoS One. 2022;17:e0267117.
    PubMed     Abstract available

  227. MEZO M, Gonzalez-Warleta M, Castro-Hermida JA, Martinez-Sernandez V, et al
    Field evaluation of the enhanced MM3-COPRO ELISA test for the diagnosis of Fasciola hepatica infection in sheep.
    PLoS One. 2022;17:e0265569.
    PubMed     Abstract available

  228. HAMADA S, Takata T, Yamada K, Yamamoto M, et al
    Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model.
    PLoS One. 2022;17:e0265461.
    PubMed     Abstract available

  229. PENG CH, Ker YB, Li HH, Tsou SH, et al
    Abelmoschus esculentus subfractions ameliorate hepatic lipogenesis and lipid uptake via regulating dipeptidyl peptidase-4-With improving insulin resistance.
    PLoS One. 2022;17:e0265444.
    PubMed     Abstract available

  230. KANEKO S, Kurosaki M, Tsuchiya K, Yasui Y, et al
    Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
    PLoS One. 2022;17:e0265235.
    PubMed     Abstract available

  231. GRASS JK, Kusters N, Kemper M, Tintrup J, et al
    Risk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience.
    PLoS One. 2022;17:e0265093.
    PubMed     Abstract available

  232. SAXENA R, Nassiri M, Yin XM, Morral N, et al
    Insights from a high-fat diet fed mouse model with a humanized liver.
    PLoS One. 2022;17:e0268260.
    PubMed     Abstract available

  233. HICKMAN TL, Choi E, Whiteman KR, Muralidharan S, et al
    BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    PLoS One. 2022;17:e0266980.
    PubMed     Abstract available

  234. OH MK, Joo H, Kim IS
    Prohaptoglobin inhibits the transforming growth factor-beta-induced epithelial-to-mesenchymal transition in vitro by increasing Smad1/5 activation and suppressing the Smad2/3 signaling pathway in SK-Hep1 liver cancer cells.
    PLoS One. 2022;17:e0266409.
    PubMed     Abstract available

  235. ORR CE, Wang PL, Chen L, Wang T, et al
    Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
    PLoS One. 2022;17:e0267474.
    PubMed     Abstract available

  236. MUCKE VT, Peiffer KH, Kessel J, Schwarzkopf KM, et al
    Impact of colonization with multidrug-resistant organisms on antibiotic prophylaxis in patients with cirrhosis and variceal bleeding.
    PLoS One. 2022;17:e0268638.
    PubMed     Abstract available

  237. ZHANG XF, Lai L, Zhou H, Mo YJ, et al
    Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis.
    PLoS One. 2022;17:e0268779.
    PubMed     Abstract available

  238. BESSHO R, Kashiwagi K, Ikura A, Yamataka K, et al
    A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    PLoS One. 2022;17:e0269265.
    PubMed     Abstract available

  239. WANG L, Ding Y, Zhang C, Chen R, et al
    Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients.
    PLoS One. 2022;17:e0269249.
    PubMed     Abstract available

  240. THEVENOT T, Vendeville S, Weil D, Akkouche L, et al
    Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.
    PLoS One. 2022;17:e0266965.
    PubMed     Abstract available

  241. LAUN FB, Fuhres T, Seuss H, Muller A, et al
    Flow-compensated diffusion encoding in MRI for improved liver metastasis detection.
    PLoS One. 2022;17:e0268843.
    PubMed     Abstract available

  242. RIDJAB DA, Ivan I, Budiman F, Tenggara R, et al
    Evaluation of subclinical ventricular systolic dysfunction assessed using global longitudinal strain in liver cirrhosis: A systematic review, meta-analysis, and meta-regression.
    PLoS One. 2022;17:e0269691.
    PubMed     Abstract available

  243. EFREMOV Y, Ermolaeva A, Vladimirov G, Gordleeva S, et al
    A mathematical model of in vitro hepatocellular cholesterol and lipoprotein metabolism for hyperlipidemia therapy.
    PLoS One. 2022;17:e0264903.
    PubMed     Abstract available

  244. LYNCH EC, Liu Z, Liu L, Wang X, et al
    Disrupting Osr1 expression promoted hepatic steatosis and inflammation induced by high-fat diet in the mouse model.
    PLoS One. 2022;17:e0268344.
    PubMed     Abstract available

  245. PARK J, Kwon HJ, Sohn W, Cho JY, et al
    Risk of liver fibrosis in patients with prediabetes and diabetes mellitus.
    PLoS One. 2022;17:e0269070.
    PubMed     Abstract available

  246. KOGISO T, Sagawa T, Taniai M, Shimada E, et al
    Risk factors for Fontan-associated hepatocellular carcinoma.
    PLoS One. 2022;17:e0270230.
    PubMed     Abstract available

  247. NABILOU P, Danielsen KV, Kimer N, Hove JD, et al
    Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
    PLoS One. 2022;17:e0270603.
    PubMed     Abstract available

  248. GUL B, Firasat S, Tehreem R, Shan T, et al
    Analysis of Wilson disease mutations in copper binding domain of ATP7B gene.
    PLoS One. 2022;17:e0269833.
    PubMed     Abstract available

  249. LO B, Marty-Gasset N, Manse H, Canlet C, et al
    Slightly different metabolomic profiles are associated with high or low weight duck foie gras.
    PLoS One. 2022;17:e0255707.
    PubMed     Abstract available

  250. HUANG YJ, Wang PM, Tang KS, Chen CJ, et al
    Butyrate ameliorates maternal high-fat diet-induced fetal liver cellular apoptosis.
    PLoS One. 2022;17:e0270657.
    PubMed     Abstract available

  251. ZUO Z, Cui H, Wang M, Huang C, et al
    Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study.
    PLoS One. 2022;17:e0270512.
    PubMed     Abstract available

  252. NAKAI M, Suda G, Ogawa K, Yoshida S, et al
    Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    PLoS One. 2022;17:e0270786.
    PubMed     Abstract available

  253. NAGASAWA T, Kuroda H, Abe T, Saiki H, et al
    Shear wave dispersion to assess liver disease progression in Fontan-associated liver disease.
    PLoS One. 2022;17:e0271223.
    PubMed     Abstract available

  254. TASCON-VIDARTE JD, Stick LB, Josipovic M, Risum S, et al
    Accuracy and consistency of intensity-based deformable image registration in 4DCT for tumor motion estimation in liver radiotherapy planning.
    PLoS One. 2022;17:e0271064.
    PubMed     Abstract available

  255. KIM N, Roh JH, Lee H, Kim D, et al
    The impact of non-alcoholic fatty liver disease on sleep apnea in healthy adults: A nationwide study of Korea.
    PLoS One. 2022;17:e0271021.
    PubMed     Abstract available

  256. WEHMEYER MH, Sekhri H, Wroblewski R, Galante A, et al
    Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis.
    PLoS One. 2022;17:e0271541.
    PubMed     Abstract available

  257. COKER T, Saxton J, Retat L, Alswat K, et al
    The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia.
    PLoS One. 2022;17:e0271108.
    PubMed     Abstract available

  258. DARADICS N, Horvath G, Tretter L, Paal A, et al
    The effect of Cyclophilin D depletion on liver regeneration following associating liver partition and portal vein ligation for staged hepatectomy.
    PLoS One. 2022;17:e0271606.
    PubMed     Abstract available

  259. JIANG Y, Zhang Y, Yang Q, Zeng D, et al
    The association between fetal fraction and pregnancy-related complications among Chinese population.
    PLoS One. 2022;17:e0271219.
    PubMed     Abstract available

  260. JANG S, Choi GH, Chang W, Jang ES, et al
    Elevated alpha-fetoprotein in asymptomatic adults: Clinical features, outcome, and association with body composition.
    PLoS One. 2022;17:e0271407.
    PubMed     Abstract available

  261. GLOWCZYNSKA R, Borodzicz-Jazdzyk S, Peller M, Raszeja-Wyszomirska J, et al
    Chronotropic incompetence in end-stage liver disease.
    PLoS One. 2022;17:e0270784.
    PubMed     Abstract available

  262. ABDULMALEK S, Mostafa N, Gomaa M, El-Kersh M, et al
    Bee venom-loaded EGFR-targeting peptide-coupled chitosan nanoparticles for effective therapy of hepatocellular carcinoma by inhibiting EGFR-mediated MEK/ERK pathway.
    PLoS One. 2022;17:e0272776.
    PubMed     Abstract available

  263. CULP WTN, Johnson EG, Giuffrida MA, Rebhun RB, et al
    Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs.
    PLoS One. 2022;17:e0269941.
    PubMed     Abstract available

  264. THI THU PN, Quynh MNT, Van HN, Thanh HN, et al
    A logistic regression model based on inpatient health records to predict drug-induced liver injury caused by ramipril-An angiotensin-converting enzyme inhibitor.
    PLoS One. 2022;17:e0272786.
    PubMed     Abstract available

  265. GURNEY J, Whitehead J, Kerrison C, Stanley J, et al
    Equity of travel required to access first definitive surgery for liver or stomach cancer in New Zealand.
    PLoS One. 2022;17:e0269593.
    PubMed     Abstract available

  266. NIEHUES MB, Tomaz LA, Ferreira MS, Baldassini WA, et al
    Assessment of corn wet distillers grains fed to crossbred bulls on feeding behavior, rumen morphology, liver abscesses and blood parameters.
    PLoS One. 2022;17:e0271461.
    PubMed     Abstract available

  267. CHENG J, Wang Z, Liu J, Dou C, et al
    Value of 3D printing technology combined with indocyanine green fluorescent navigation in complex laparoscopic hepatectomy.
    PLoS One. 2022;17:e0272815.
    PubMed     Abstract available

  268. YOKOKAWA T, Sasaki S, Sase K, Yoshii N, et al
    Association of serum brain-derived neurotrophic factor with hepatic enzymes, AST/ALT ratio, and FIB-4 index in middle-aged and older women.
    PLoS One. 2022;17:e0273056.
    PubMed     Abstract available

  269. HYMEL E, Vlock E, Fisher KW, Farazi PA, et al
    Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
    PLoS One. 2022;17:e0272623.
    PubMed     Abstract available

  270. TANAKA S, De Tymowski C, Stern J, Bouzid D, et al
    Relationship between liver dysfunction, lipoprotein concentration and mortality during sepsis.
    PLoS One. 2022;17:e0272352.
    PubMed     Abstract available

  271. YANG X, Xia Y, Wang S, Sun C, et al
    Prognostic value of SPARC in hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0273317.
    PubMed     Abstract available

  272. SO B, Ji LL, Imdad S, Kang C, et al
    Proteomic analysis of the effect of high-fat-diet and voluntary physical activity on mouse liver.
    PLoS One. 2022;17:e0273049.
    PubMed     Abstract available

  273. ZHANG H, Gao J
    Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis.
    PLoS One. 2022;17:e0273231.
    PubMed     Abstract available

  274. KARMACHARYA MB, Hada B, Park SR, Kim KH, et al
    Granulocyte-macrophage colony-stimulating factor (GM-CSF) shows therapeutic effect on dimethylnitrosamine (DMN)-induced liver fibrosis in rats.
    PLoS One. 2022;17:e0274126.
    PubMed     Abstract available

  275. NASERALALLAH LM, Aboujabal BA, Geryo NM, Al Boinin A, et al
    The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome.
    PLoS One. 2022;17:e0268705.
    PubMed     Abstract available

  276. ASATURYAN HA, Basty N, Thanaj M, Whitcher B, et al
    Improving the accuracy of fatty liver index to reflect liver fat content with predictive regression modelling.
    PLoS One. 2022;17:e0273171.
    PubMed     Abstract available

  277. HENDRYX M, Dong Y, Ndeke JM, Luo J, et al
    Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.
    PLoS One. 2022;17:e0274519.
    PubMed     Abstract available

  278. LASCANO J, Oshins R, Eagan C, Wadood Z, et al
    Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection.
    PLoS One. 2022;17:e0274427.
    PubMed     Abstract available

  279. WEIHER M, Richtering FG, Dorffel Y, Muller HP, et al
    Simplification of 2D shear wave elastography by enlarged SWE box and multiple regions of interest in one acquisition.
    PLoS One. 2022;17:e0273769.
    PubMed     Abstract available

  280. LEE J, Park SB, Byun S, Kim HI, et al
    Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance.
    PLoS One. 2022;17:e0274747.
    PubMed     Abstract available

  281. KANN AE, Ba-Ali S, Seidelin JB, Larsen FS, et al
    The effect of induced hyperammonaemia on sleep and melanopsin-mediated pupillary light response in patients with liver cirrhosis: A single-blinded randomized crossover trial.
    PLoS One. 2022;17:e0275067.
    PubMed     Abstract available

  282. SITTHIRACH C, Charoensuk L, Pairojkul C, Chaidee A, et al
    Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with Opisthorchis viverrini.
    PLoS One. 2022;17:e0275273.
    PubMed     Abstract available

  283. XU J, Ma H, Shan B
    Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
    PLoS One. 2022;17:e0273163.
    PubMed     Abstract available

  284. ISHII M, Tominaga T, Nonaka T, Oyama S, et al
    Colon inflammatory index as a useful prognostic marker after R0 resection in patients with colorectal cancer liver metastasis.
    PLoS One. 2022;17:e0273167.
    PubMed     Abstract available

  285. TILLMANN HL, Suzuki A, Merz M, Hermann R, et al
    A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).
    PLoS One. 2022;17:e0271304.
    PubMed     Abstract available

  286. HAGEMANN CA, Legart C, Mollerhoj MB, Madsen MR, et al
    A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity.
    PLoS One. 2022;17:e0275901.
    PubMed     Abstract available

  287. WU L, Zhuang J, Chen W, Tang Y, et al
    Data augmentation based on multiple oversampling fusion for medical image segmentation.
    PLoS One. 2022;17:e0274522.
    PubMed     Abstract available

  288. LE BOUTILLIER C, Ahmed H, Patel VC, McPhail M, et al
    General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial.
    PLoS One. 2022;17:e0275668.
    PubMed     Abstract available

  289. CHIDLOW SJ, Randle LE, Kelly RA
    Predicting physiologically-relevant oxygen concentrations in precision-cut liver slices using mathematical modelling.
    PLoS One. 2022;17:e0275788.
    PubMed     Abstract available

  290. LIN N, Wang L, Huang Q, Zhou W, et al
    A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0276627.
    PubMed     Abstract available

  291. LU Z, Li Y, Li AJ, Syn WK, et al
    Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis.
    PLoS One. 2022;17:e0277251.
    PubMed     Abstract available

  292. COLAK N, Bayrak Basakci O, Bayram B, Aksay E, et al
    Optic nerve sheath diameter in patients with hepatic encephalopathy.
    PLoS One. 2022;17:e0277643.
    PubMed     Abstract available

  293. SHEARN CT, Anderson AL, Devereux MW, Orlicky DJ, et al
    The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease.
    PLoS One. 2022;17:e0276879.
    PubMed     Abstract available

  294. GROBBEE EJ, de Jong VD, Schrieks IC, Tushuizen ME, et al
    Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-alpha/gamma agonist aleglitazar.
    PLoS One. 2022;17:e0277706.
    PubMed     Abstract available

  295. MENA E, Shih J, Chung JY, Jones J, et al
    Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0277407.
    PubMed     Abstract available

  296. KIYOAKI I, Sumida Y, Nakade Y, Okumura A, et al
    Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis.
    PLoS One. 2022;17:e0277380.
    PubMed     Abstract available

  297. LAOCHAREONSUK W, Surachat K, Chiengkriwate P, Sangkhathat S, et al
    A novel pathogenesis concept of biliary atresia approached by combined molecular strategies.
    PLoS One. 2022;17:e0277334.
    PubMed     Abstract available

  298. WANG S, Wang G, Lu S, Zhang J, et al
    Proteome expression profiling of red blood cells during the tumorigenesis of hepatocellular carcinoma.
    PLoS One. 2022;17:e0276904.
    PubMed     Abstract available

  299. TATEDA T, Iino C, Sasada T, Sato S, et al
    Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study.
    PLoS One. 2022;17:e0277930.
    PubMed     Abstract available

  300. TEERASARNTIPAN T, Thanapirom K, Chirapongsathorn S, Suttichaimongkol T, et al
    Validation of prognostic scores predicting mortality in acute liver decompensation or acute-on-chronic liver failure: A Thailand multicenter study.
    PLoS One. 2022;17:e0277959.
    PubMed     Abstract available

  301. DENK A, Muller K, Schlosser S, Heissner K, et al
    Liver diseases as a novel risk factor for delirium in the ICU-Delirium and hepatic encephalopathy are two distinct entities.
    PLoS One. 2022;17:e0276914.
    PubMed     Abstract available

  302. MIWA T, Hanai T, Nishimura K, Maeda T, et al
    A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis.
    PLoS One. 2022;17:e0277829.
    PubMed     Abstract available

  303. GURNEY J, Stanley J, Teng A, Krebs J, et al
    Cancer and diabetes co-occurrence: A national study with 44 million person-years of follow-up.
    PLoS One. 2022;17:e0276913.
    PubMed     Abstract available

  304. JIN M, Jiang Y, Zhao Q, Pan Z, et al
    Diagnostic value of T2 relaxation time for hepatic iron grading in rat model of fatty and fibrotic liver.
    PLoS One. 2022;17:e0278574.
    PubMed     Abstract available

  305. FARKKILA M, Kautiainen H, Tenca A, Jokelainen K, et al
    PNPLA3 allele frequency has no impact on biliary bile acid composition or disease course in patients with primary sclerosing cholangitis.
    PLoS One. 2022;17:e0277084.
    PubMed     Abstract available

  306. DUNGUBAT E, Kusano H, Mori I, Tawara H, et al
    Age-dependent sex difference of non-alcoholic fatty liver disease in TSOD and db/db mice.
    PLoS One. 2022;17:e0278580.
    PubMed     Abstract available

  307. CHOI SW, Kweon SS, Lee YH, Ryu SY, et al
    Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study.
    PLoS One. 2022;17:e0277729.
    PubMed     Abstract available

  308. SEO GH, Yoo JJ
    Incidence of major depressive disorder over time in patients with liver cirrhosis: A nationwide population-based study in Korea.
    PLoS One. 2022;17:e0278924.
    PubMed     Abstract available

  309. LIU SY, Huang CC, Yang YY, Huang SF, et al
    Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
    PLoS One. 2022;17:e0276717.
    PubMed     Abstract available

  310. NAH EH, Shin SK, Cho S, Park H, et al
    Chronic kidney disease in nonalcoholic fatty liver disease at primary healthcare centers in Korea.
    PLoS One. 2022;17:e0279367.
    PubMed     Abstract available

  311. HEINTZ MM, Eccles JA, Olack EM, Maner-Smith KM, et al
    Human CYP2B6 produces oxylipins from polyunsaturated fatty acids and reduces diet-induced obesity.
    PLoS One. 2022;17:e0277053.
    PubMed     Abstract available

  312. SHAHZADI I, Zahoor AF, Tuzun B, Mansha A, et al
    Repositioning of acefylline as anti-cancer drug: Synthesis, anticancer and computational studies of azomethines derived from acefylline tethered 4-amino-3-mercapto-1,2,4-triazole.
    PLoS One. 2022;17:e0278027.
    PubMed     Abstract available

  313. DAI X, Zhou G, Xu L
    Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease(MAFLD).
    PLoS One. 2022;17:e0279274.
    PubMed     Abstract available

  314. KIM KW, Kang HW, Yoo H, Jun Y, et al
    Association between severe hepatic steatosis examined by Fibroscan and the risk of high-risk colorectal neoplasia.
    PLoS One. 2022;17:e0279242.
    PubMed     Abstract available

  315. GAO Y, Qian B, Zhang X, Liu H, et al
    Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: A meta-analysis.
    PLoS One. 2022;17:e0279496.
    PubMed     Abstract available

  316. WANG Z, Pei Y, Li W, Zhang J, et al
    Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0279591.
    PubMed     Abstract available

    January 2021
  317. OHIRA S, Kanayama N, Wada K, Ikawa T, et al
    Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography.
    PLoS One. 2021;16:e0244079.
    PubMed     Abstract available

  318. ZHAO N, Tan H, Wang L, Han L, et al
    Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes.
    PLoS One. 2021;16:e0243938.
    PubMed     Abstract available

  319. SETO WK, Mandell MS
    Chronic liver disease: Global perspectives and future challenges to delivering quality health care.
    PLoS One. 2021;16:e0243607.

  320. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West.
    PLoS One. 2021;16:e0244939.
    PubMed     Abstract available

  321. LI X, Zhong X, Wang Y, Zeng X, et al
    Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0250602.
    PubMed     Abstract available

  322. FERSTL PG, Filmann N, Heilgenthal EM, Schnitzbauer AA, et al
    Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.
    PLoS One. 2021;16:e0245091.
    PubMed     Abstract available

  323. DA FONSECA RD, Santos PR, Monteiro MS, Fernandes LA, et al
    Parametric evaluation of impedance curve in radiofrequency ablation: A quantitative description of the asymmetry and dynamic variation of impedance in bovine ex vivo model.
    PLoS One. 2021;16:e0245145.
    PubMed     Abstract available

  324. FRANKOVA S, Lunova M, Gottfriedova H, Senkerikova R, et al
    Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis.
    PLoS One. 2021;16:e0244934.
    PubMed     Abstract available

  325. WANG F, Numata K, Takeda A, Ogushi K, et al
    Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.
    PLoS One. 2021;16:e0245076.
    PubMed     Abstract available

  326. CARTER JK, Bhattacharya D, Borgerding JN, Fiel MI, et al
    Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
    PLoS One. 2021;16:e0244763.
    PubMed     Abstract available

  327. JOBIRA B, Frank DN, Silveira LJ, Pyle L, et al
    Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome.
    PLoS One. 2021;16:e0245219.
    PubMed     Abstract available

  328. FATTAHI N, Rezaei N, Asadi-Lari M, Yousefi M, et al
    Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis.
    PLoS One. 2021;16:e0245468.
    PubMed     Abstract available

  329. VAN AMERONGEN MJ, Vos AM, van der Woude W, Nagtegaal ID, et al
    Does perfusion computed tomography correlate to pathology in colorectal liver metastases?
    PLoS One. 2021;16:e0245764.
    PubMed     Abstract available

  330. CHENG K, Liu W, You J, Shah S, et al
    Safety of laparoscopic pancreaticoduodenectomy in patients with liver cirrhosis using propensity score matching.
    PLoS One. 2021;16:e0246364.
    PubMed     Abstract available

  331. CHO Y, Lee S, Park SJ
    Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization.
    PLoS One. 2021;16:e0245911.
    PubMed     Abstract available

  332. LIN X, You F, Liu H, Fang Y, et al
    Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0245921.
    PubMed     Abstract available

  333. CHEN BW, Chiu GW, He YC, Huang CY, et al
    Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid.
    PLoS One. 2021;16:e0245286.
    PubMed     Abstract available

  334. NIRIELLA MA, Ediriweera DS, Kasturiratne A, De Silva ST, et al
    Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.
    PLoS One. 2021;16:e0245762.
    PubMed     Abstract available

  335. MENDOZA N, Rivas E, Rodriguez-Roisin R, Garcia T, et al
    Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study.
    PLoS One. 2021;16:e0245046.
    PubMed     Abstract available

  336. VOGL TJ, Riegelbauer LJ, Oppermann E, Kostantin M, et al
    Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma.
    PLoS One. 2021;16:e0246527.
    PubMed     Abstract available

  337. SEO N, Park MS, Choi JY, Yeom JS, et al
    A prospective study on the use of ultralow-dose computed tomography with iterative reconstruction for the follow-up of patients liver and renal abscess.
    PLoS One. 2021;16:e0246532.
    PubMed     Abstract available

  338. ASSIS JB, Cogliati B, Esteves E, Capurro ML, et al
    Aedes aegypti mosquito saliva ameliorates acetaminophen-induced liver injury in mice.
    PLoS One. 2021;16:e0245788.
    PubMed     Abstract available

  339. TANAKA T, Hirooka M, Koizumi Y, Watanabe T, et al
    Development of a method for measuring spleen stiffness by transient elastography using a new device and ultrasound-fusion method.
    PLoS One. 2021;16:e0246315.
    PubMed     Abstract available

  340. KIM YA, Kang D, Moon H, Sinn D, et al
    Survival in untreated hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0246143.
    PubMed     Abstract available

  341. FUKUYAMA K, Asagiri M, Sugimoto M, Tsushima H, et al
    Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters.
    PLoS One. 2021;16:e0245939.
    PubMed     Abstract available

  342. STAHLSCHMIDT FL, Tafarel JR, Menini-Stahlschmidt CM, Baena CP, et al
    Hepatorenal index for grading liver steatosis with concomitant fibrosis.
    PLoS One. 2021;16:e0246837.
    PubMed     Abstract available

  343. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic value of future liver remnant LU15 index of 99mTc-galactosyl serum albumin scintigraphy for predicting posthepatectomy liver failure.
    PLoS One. 2021;16:e0247675.
    PubMed     Abstract available

  344. KOVAC JD, Dakovic M, Jankovic A, Mitrovic M, et al
    The role of quantitative diffusion-weighted imaging in characterization of hypovascular liver lesions: A prospective comparison of intravoxel incoherent motion derived parameters and apparent diffusion coefficient.
    PLoS One. 2021;16:e0247301.
    PubMed     Abstract available

  345. KIMANYA ME, Routledge MN, Mpolya E, Ezekiel CN, et al
    Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data.
    PLoS One. 2021;16:e0247281.
    PubMed     Abstract available

  346. CHO WR, Wang CC, Tsai MY, Chou CK, et al
    Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients.
    PLoS One. 2021;16:e0247231.
    PubMed     Abstract available

  347. POMEJ K, Scheiner B, Hartl L, Balcar L, et al
    COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital.
    PLoS One. 2021;16:e0256544.
    PubMed     Abstract available

  348. SHIGESAWA T, Suda G, Kimura M, Maehara O, et al
    Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    PLoS One. 2021;16:e0247728.
    PubMed     Abstract available

  349. NAKADE Y, Kitano R, Sakamoto K, Kimoto S, et al
    Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats.
    PLoS One. 2021;16:e0247303.
    PubMed     Abstract available

  350. TAKASE T, Toyoda T, Kobayashi N, Inoue T, et al
    Dietary iso-alpha-acids prevent acetaldehyde-induced liver injury through Nrf2-mediated gene expression.
    PLoS One. 2021;16:e0246327.
    PubMed     Abstract available

  351. HODEIFY R, Chakkour M, Rida R, Kreydiyyeh S, et al
    PGE2 upregulates the Na+/K+ ATPase in HepG2 cells via EP4 receptors and intracellular calcium.
    PLoS One. 2021;16:e0245400.
    PubMed     Abstract available

  352. KURODA H, Fujiwara Y, Abe T, Nagasawa T, et al
    Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis.
    PLoS One. 2021;16:e0249493.
    PubMed     Abstract available

  353. D'AMBROSIO R, Campi I, Maggioni M, Perbellini R, et al
    The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).
    PLoS One. 2021;16:e0249614.
    PubMed     Abstract available

  354. BUSQUETS-CORTES C, Bennasar-Veny M, Lopez-Gonzalez AA, Fresneda S, et al
    Utility of Fatty Liver Index to predict reversion to normoglycemia in people with prediabetes.
    PLoS One. 2021;16:e0249221.
    PubMed     Abstract available

  355. BEYER C, Hutton C, Andersson A, Imajo K, et al
    Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort.
    PLoS One. 2021;16:e0249491.
    PubMed     Abstract available

  356. KAPS L, Ahlbrand CJ, Gadban R, Nagel M, et al
    Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care.
    PLoS One. 2021;16:e0249342.
    PubMed     Abstract available

  357. ARIYA M, Koohpayeh F, Ghaemi A, Osati S, et al
    Assessment of the association between body composition and risk of non-alcoholic fatty liver.
    PLoS One. 2021;16:e0249223.
    PubMed     Abstract available

  358. CHEN Y, Xu Z, Zeng Y, Liu J, et al
    Altered metabolism by autophagy defection affect liver regeneration.
    PLoS One. 2021;16:e0250578.
    PubMed     Abstract available

  359. TAHA MM, Aneis YM, Mohamady HM, S A A, et al
    Effect of focused ultrasound cavitation augmented with aerobic exercise on abdominal and intrahepatic fat in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
    PLoS One. 2021;16:e0250337.
    PubMed     Abstract available

  360. KOUTOUKIDIS DA, Morris E, Henry JA, Shammoon Y, et al
    What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0250385.
    PubMed     Abstract available

  361. NAYAN SI, Chowdhury FI, Akter N, Rahman MM, et al
    Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats.
    PLoS One. 2021;16:e0250261.
    PubMed     Abstract available

  362. WANG R, Hu X, Liu X, Bai L, et al
    Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    PLoS One. 2021;16:e0249881.
    PubMed     Abstract available

  363. PARK JW, Jeong JM, Cho KS, Cho SY, et al
    MiR-30a and miR-200c differentiate cholangiocarcinomas from gastrointestinal cancer liver metastases.
    PLoS One. 2021;16:e0250083.
    PubMed     Abstract available

  364. HOSHI H, Chu PS, Yoshida A, Taniki N, et al
    Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis.
    PLoS One. 2021;16:e0250062.
    PubMed     Abstract available

  365. KIM JY, Park YM, Lee GN, Song HC, et al
    Association between toothbrushing and non-alcoholic fatty liver disease.
    PLoS One. 2021;16:e0243686.
    PubMed     Abstract available

  366. MAHRINGER-KUNZ A, Steinle V, Kloeckner R, Schotten S, et al
    The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
    PLoS One. 2021;16:e0249426.
    PubMed     Abstract available

  367. NG YZ, Lai LL, Wong SW, Mohamad SY, et al
    Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease.
    PLoS One. 2021;16:e0250300.
    PubMed     Abstract available

  368. EDER M, Omic H, Gorges J, Badt F, et al
    Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease.
    PLoS One. 2021;16:e0249785.
    PubMed     Abstract available

  369. SAEKI C, Saito M, Kanai T, Nakano M, et al
    Plasma pentosidine levels are associated with prevalent fractures in patients with chronic liver disease.
    PLoS One. 2021;16:e0249728.
    PubMed     Abstract available

  370. SENGUPTA M, Abuirqeba S, Kameric A, Cecile-Valfort A, et al
    A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis.
    PLoS One. 2021;16:e0249316.
    PubMed     Abstract available

  371. KEHL T, Biermann D, Briem-Richter A, Schoen G, et al
    Impact of hepatopathy in pediatric patients after surgery for complex congenital heart disease.
    PLoS One. 2021;16:e0248776.
    PubMed     Abstract available

  372. LIN SY, Chen CM, Huang BS, Lai YC, et al
    A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness.
    PLoS One. 2021;16:e0249003.
    PubMed     Abstract available

  373. MISHIMA K, Itano O, Matsuda S, Suzuki S, et al
    Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model.
    PLoS One. 2021;16:e0248352.
    PubMed     Abstract available

  374. HUANG CY, Chang YJ, Wei PL, Hung CS, et al
    Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells.
    PLoS One. 2021;16:e0248521.
    PubMed     Abstract available

  375. LOOSEN SH, Castoldi M, Jordens MS, Roy S, et al
    Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC.
    PLoS One. 2021;16:e0247917.
    PubMed     Abstract available

  376. DE MUNCK TJI, Boesch M, Verhaegh P, Masclee AAM, et al
    Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?
    PLoS One. 2021;16:e0251822.
    PubMed     Abstract available

  377. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias.
    PLoS One. 2021;16:e0249194.
    PubMed     Abstract available

  378. LEMIEUX S, Buies A, F Turgeon A, Hallet J, et al
    Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0247958.
    PubMed     Abstract available

  379. MORAN MW, Ramirez EP, Zook JD, Saarinen AM, et al
    Biophysical characterization and a roadmap towards the NMR solution structure of G0S2, a key enzyme in non-alcoholic fatty liver disease.
    PLoS One. 2021;16:e0249164.
    PubMed     Abstract available

  380. JUSTINO AB, Florentino RM, Franca A, Filho ACML, et al
    Alkaloid and acetogenin-rich fraction from Annona crassiflora fruit peel inhibits proliferation and migration of human liver cancer HepG2 cells.
    PLoS One. 2021;16:e0250394.
    PubMed     Abstract available

  381. ZHANG X, Heredia NI, Balakrishnan M, Thrift AP, et al
    Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
    PLoS One. 2021;16:e0252164.
    PubMed     Abstract available

  382. BERNARDO S, Crespo R, Saraiva S, Barata R, et al
    Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality.
    PLoS One. 2021;16:e0252218.
    PubMed     Abstract available

  383. BROERING D, Shawkat M, Albenmousa A, Abaalkhail F, et al
    Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors.
    PLoS One. 2021;16:e0251487.
    PubMed     Abstract available

  384. PEREIRA R, Buglevski M, Perdigoto R, Marcelino P, et al
    Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.
    PLoS One. 2021;16:e0251498.
    PubMed     Abstract available

  385. YOUNG P, Tarce P, Adhikary S, Connolly J, et al
    Evaluation of high-resolution melt curve analysis for rapid differentiation of Campylobacter hepaticus from other species in birds.
    PLoS One. 2021;16:e0251328.
    PubMed     Abstract available

  386. HE Y, Xu R, Peng L, Hu X, et al
    Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis.
    PLoS One. 2021;16:e0254829.
    PubMed     Abstract available

  387. DAYTON KA, Bril F, Barb D, Lai J, et al
    Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
    PLoS One. 2021;16:e0251449.
    PubMed     Abstract available

  388. KAPS L, Hildebrand K, Nagel M, Michel M, et al
    Risk factors for poorer health literacy in patients with liver cirrhosis.
    PLoS One. 2021;16:e0255349.
    PubMed     Abstract available

  389. LEE Y, Mun E, Park S, Lee W, et al
    Long working hours are associated with a higher risk of non-alcoholic fatty liver disease: A large population-based Korean cohort study.
    PLoS One. 2021;16:e0255118.
    PubMed     Abstract available

  390. HALFON P, Ansaldi C, Penaranda G, Chiche L, et al
    Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
    PLoS One. 2021;16:e0254939.
    PubMed     Abstract available

  391. KHORPRASERT C, Thonglert K, Alisanant P, Amornwichet N, et al
    Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes.
    PLoS One. 2021;16:e0257556.
    PubMed     Abstract available

  392. WEN X, Wang S, Taveira TH, Akhlaghi F, et al
    Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH).
    PLoS One. 2021;16:e0251665.
    PubMed     Abstract available

  393. COUBARD OA, Ober KM, Gaumet M, Urbanski M, et al
    Standardization of the psychometric hepatic encephalopathy score in a French population.
    PLoS One. 2021;16:e0257136.
    PubMed     Abstract available

  394. CHANG Y, Han JA, Kang SM, Jeong SW, et al
    Clinical impact of serum exosomal microRNA in liver fibrosis.
    PLoS One. 2021;16:e0255672.
    PubMed     Abstract available

  395. GAO L, Morine Y, Yamada S, Saito Y, et al
    Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    PLoS One. 2021;16:e0256755.
    PubMed     Abstract available

  396. WAQAR W, Asghar S, Manzoor S
    Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules.
    PLoS One. 2021;16:e0256739.
    PubMed     Abstract available

  397. STRUCK MF, Kliem P, Ebel S, Bauer A, et al
    Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery.
    PLoS One. 2021;16:e0254817.
    PubMed     Abstract available

  398. SUKAHRI S, Mohamed Shah FZ, Ismail AI, Koshy M, et al
    Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease.
    PLoS One. 2021;16:e0253298.
    PubMed     Abstract available

  399. SHI X, Li J, Min B, Yang R, et al
    Application of ultrasound elastography for monitoring the effects of TbetaR1 shRNA therapy on hepatic fibrosis in a rat model.
    PLoS One. 2021;16:e0253150.
    PubMed     Abstract available

  400. SHIMIZU Y, Sasaki T, Takeshita JI, Watanabe M, et al
    Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs.
    PLoS One. 2021;16:e0253855.
    PubMed     Abstract available

  401. LEE JW, Hwang JS, Chung WJ, Lee HJ, et al
    Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites.
    PLoS One. 2021;16:e0253886.
    PubMed     Abstract available

  402. REIMER RP, Hokamp NG, Niehoff J, Zopfs D, et al
    Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.
    PLoS One. 2021;16:e0252678.
    PubMed     Abstract available

  403. JO HH, Min C, Kyoung DS, Park MA, et al
    Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.
    PLoS One. 2021;16:e0253165.
    PubMed     Abstract available

  404. TIYARATTANACHAI T, Apiparakoon T, Marukatat S, Sukcharoen S, et al
    Development and validation of artificial intelligence to detect and diagnose liver lesions from ultrasound images.
    PLoS One. 2021;16:e0252882.
    PubMed     Abstract available

  405. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2021;16:e0252537.
    PubMed     Abstract available

  406. ZHOU J, Zhu Y, Ma S, Li Y, et al
    Bioinformatics analysis identifies DYNC1I1 as prognosis marker in male patients with liver hepatocellular carcinoma.
    PLoS One. 2021;16:e0258797.
    PubMed     Abstract available

  407. XIE Y, Liu C, Zhang Y, Li A, et al
    PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
    PLoS One. 2021;16:e0258817.
    PubMed     Abstract available

  408. HSU PK, Wu LS, Su WW, Su PY, et al
    Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis.
    PLoS One. 2021;16:e0254892.
    PubMed     Abstract available

  409. ISOURA Y, Yamamoto A, Cho Y, Ehara E, et al
    Platelet count and abdominal dynamic CT are useful in predicting and screening for gastroesophageal varices after Fontan surgery.
    PLoS One. 2021;16:e0257441.
    PubMed     Abstract available

  410. WANG Y, Xiao X, Wang X, Guo F, et al
    Identification of differentially expressed long noncoding RNAs and pathways in liver tissues from rats with hepatic fibrosis.
    PLoS One. 2021;16:e0258194.
    PubMed     Abstract available

  411. KHAMIS ZI, Pang X, Cui Z, Sang QA, et al
    Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity.
    PLoS One. 2021;16:e0257072.
    PubMed     Abstract available

  412. CHUAYPEN N, Limothai U, Kunadirek P, Kaewsapsak P, et al
    Identification and validation of circulating miRNAs as potential new biomarkers for severe liver disease in patients with leptospirosis.
    PLoS One. 2021;16:e0257805.
    PubMed     Abstract available

  413. PARK JH, Chung YE, Seo N, Choi JY, et al
    Hepatobiliary phase signal intensity: A potential method of diagnosing HCC with atypical imaging features among LR-M observations.
    PLoS One. 2021;16:e0257308.
    PubMed     Abstract available

  414. LI M, Hu M, Yue Z, Zhang Y, et al
    The interactive effects of non-alcoholic fatty liver disease and hemoglobin concentration in the first trimester on the development of gestational diabetes mellitus.
    PLoS One. 2021;16:e0257391.
    PubMed     Abstract available

  415. BHATT SP, Guleria R
    Association of IRS1 (Gly972Arg) and IRS2 (Gly1057Asp) genes polymorphisms with OSA and NAFLD in Asian Indians.
    PLoS One. 2021;16:e0245408.
    PubMed     Abstract available

  416. HUNOLD P, Berg T, Seehofer D, Sucher R, et al
    Experiences from six years of quality assured Model of End Stage Liver Disease (MELD) diagnostics.
    PLoS One. 2021;16:e0254219.
    PubMed     Abstract available

  417. YANG CJ, Wang CK, Fang YD, Wang JY, et al
    Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets.
    PLoS One. 2021;16:e0255605.
    PubMed     Abstract available

  418. MINICOZZI MR, Axlid EG, von Hippel FA, Espinoza J, et al
    Perchlorate exposure does not induce obesity or non-alcoholic fatty liver disease in zebrafish.
    PLoS One. 2021;16:e0254500.
    PubMed     Abstract available

  419. WU PS, Hsieh YC, Lee KC, Huang YH, et al
    Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients.
    PLoS One. 2021;16:e0258589.
    PubMed     Abstract available

  420. KOO DJ, Lee MY, Jung I, Moon SJ, et al
    Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study.
    PLoS One. 2021;16:e0255535.
    PubMed     Abstract available

  421. TRAN BV, Ujita K, Taketomi-Takahashi A, Hirasawa H, et al
    Reliability of ultrasound hepatorenal index and magnetic resonance imaging proton density fat fraction techniques in the diagnosis of hepatic steatosis, with magnetic resonance spectroscopy as the reference standard.
    PLoS One. 2021;16:e0255768.
    PubMed     Abstract available

  422. KITAZAWA A, Maeda S, Fukuda Y
    Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data.
    PLoS One. 2021;16:e0257352.
    PubMed     Abstract available

  423. STARITZBICHLER R, Hunold P, Estrela-Lopis I, Hildebrand PW, et al
    Raman spectroscopy on blood serum samples of patients with end-stage liver disease.
    PLoS One. 2021;16:e0256045.
    PubMed     Abstract available

  424. FREISE C, Lee H, Chronowski C, Chan D, et al
    Alpha-single chains of collagen type VI inhibit the fibrogenic effects of triple helical collagen VI in hepatic stellate cells.
    PLoS One. 2021;16:e0254557.
    PubMed     Abstract available

  425. GUO A, Mazumder NR, Ladner DP, Foraker RE, et al
    Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning.
    PLoS One. 2021;16:e0256428.
    PubMed     Abstract available

  426. UHLIG M, Hein M, Habigt MA, Tolba RH, et al
    Acute myocardial injury secondary to severe acute liver failure: A retrospective analysis supported by animal data.
    PLoS One. 2021;16:e0256790.
    PubMed     Abstract available

  427. CHERCHI V, Vetrugno L, Terrosu G, Zanini V, et al
    Association between the donor to recipient ICG-PDR variation rate and the functional recovery of the graft after orthotopic liver transplantation: A case series.
    PLoS One. 2021;16:e0256786.
    PubMed     Abstract available

  428. QUECK A, Uschner FE, Ferstl PG, Schulz M, et al
    Role of circulating angiogenin levels in portal hypertension and TIPS.
    PLoS One. 2021;16:e0256473.
    PubMed     Abstract available

  429. GARCIA-CHAVEZ JN, Vasquez-Garzon VR, Lopez MG, Villa-Trevino S, et al
    Integration of chronological omics data reveals mitochondrial regulatory mechanisms during the development of hepatocellular carcinoma.
    PLoS One. 2021;16:e0256016.
    PubMed     Abstract available

  430. MARINI TJ, Oppenheimer DC, Baran TM, Rubens DJ, et al
    Testing telediagnostic right upper quadrant abdominal ultrasound in Peru: A new horizon in expanding access to imaging in rural and underserved areas.
    PLoS One. 2021;16:e0255919.
    PubMed     Abstract available

  431. GIM JA, Bang SM, Lee YS, Lee Y, et al
    Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression.
    PLoS One. 2021;16:e0255822.
    PubMed     Abstract available

  432. BI J, Guo Y, Li Q, Liu L, et al
    Role of long intergenic non-protein coding RNA 01857 in hepatocellular carcinoma malignancy via the regulation of the microRNA-197-3p/anterior GRadient 2 axis.
    PLoS One. 2021;16:e0258312.
    PubMed     Abstract available

  433. ALBAKHEET SS, Lee MJ, Yoon H, Shin HJ, et al
    Psoas muscle area and paraspinal muscle fat in children and young adults with or without obesity and fatty liver.
    PLoS One. 2021;16:e0259948.
    PubMed     Abstract available

  434. GORJI-BAHRI G, Moradtabrizi N, Hashemi A
    Uncovering the stability status of the reputed reference genes in breast and hepatic cancer cell lines.
    PLoS One. 2021;16:e0259669.
    PubMed     Abstract available

  435. BULUT G, Guner Oytun M, Almuradova E, Harman M, et al
    Contribution of "complete response to treatment" to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis.
    PLoS One. 2021;16:e0259622.
    PubMed     Abstract available

  436. SCHOLER D, Castoldi M, Jordens MS, Schulze-Hagen M, et al
    Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series.
    PLoS One. 2021;16:e0255983.
    PubMed     Abstract available

  437. MAREK G, Collinsworth A, Liu C, Brantly M, et al
    Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.
    PLoS One. 2021;16:e0256117.
    PubMed     Abstract available

  438. LEE SW, Kim SM, Hur W, Kang BY, et al
    Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway.
    PLoS One. 2021;16:e0261067.
    PubMed     Abstract available

  439. RADY B, Nishio T, Dhar D, Liu X, et al
    PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.
    PLoS One. 2021;16:e0260721.
    PubMed     Abstract available

  440. SVECIC A, Mansour R, Tang A, Kadoury S, et al
    Prediction of post transarterial chemoembolization MR images of hepatocellular carcinoma using spatio-temporal graph convolutional networks.
    PLoS One. 2021;16:e0259692.
    PubMed     Abstract available

  441. KUANG L, Zhou W, Jiang Y
    Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis.
    PLoS One. 2021;16:e0260479.
    PubMed     Abstract available

  442. HAN JW, Sung PS, Jang JW, Choi JY, et al
    Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma.
    PLoS One. 2021;16:e0260311.
    PubMed     Abstract available

  443. ESKRIDGE W, Vierling JM, Gosbee W, Wan GA, et al
    Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE).
    PLoS One. 2021;16:e0260320.
    PubMed     Abstract available

  444. MOSTAFA RE, Shaffie NM, Allam RM
    Panax Ginseng alleviates thioacetamide-induced liver injury in ovariectomized rats: Crosstalk between inflammation and oxidative stress.
    PLoS One. 2021;16:e0260507.
    PubMed     Abstract available

  445. NAH EH, Cho S, Park H, Noh D, et al
    Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
    PLoS One. 2021;16:e0260477.
    PubMed     Abstract available

  446. GOYALE A, Jain A, Smith C, Papatheodoridi M, et al
    Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.
    PLoS One. 2021;16:e0260313.
    PubMed     Abstract available

  447. JANG DK, Ahn DW, Lee KL, Kim BG, et al
    Impacts of body composition parameters and liver cirrhosis on the severity of alcoholic acute pancreatitis.
    PLoS One. 2021;16:e0260309.
    PubMed     Abstract available

  448. TAKASU C, Yamashita S, Morine Y, Yoshikawa K, et al
    The role of the immunoescape in colorectal cancer liver metastasis.
    PLoS One. 2021;16:e0259940.
    PubMed     Abstract available

  449. NAKAGOMI R, Tateishi R, Mikami S, Wake T, et al
    Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics.
    PLoS One. 2021;16:e0259641.
    PubMed     Abstract available

  450. ABDEL-RAHMAN RF, Fayed HM, Asaad GF, Ogaly HA, et al
    The involvement of TGF-beta1 /FAK/alpha-SMA pathway in the antifibrotic impact of rice bran oil on thioacetamide-induced liver fibrosis in rats.
    PLoS One. 2021;16:e0260130.
    PubMed     Abstract available

  451. BARTON JC, Barton JC, Patel N, McLaren GD, et al
    Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.
    PLoS One. 2021;16:e0261690.
    PubMed     Abstract available

  452. AGBALAJOBI OM, Gmelin T, Moon AM, Alexandre W, et al
    Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action.
    PLoS One. 2021;16:e0261377.
    PubMed     Abstract available

  453. HAN YM, Lee J, Choi JM, Kwak MS, et al
    The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors.
    PLoS One. 2021;16:e0260994.
    PubMed     Abstract available

  454. DERMAUW V, Muchai J, Al Kappany Y, Fajardo Castaneda AL, et al
    Human fascioliasis in Africa: A systematic review.
    PLoS One. 2021;16:e0261166.
    PubMed     Abstract available

  455. GROSS M, Spektor M, Jaffe A, Kucukkaya AS, et al
    Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging.
    PLoS One. 2021;16:e0260630.
    PubMed     Abstract available

  456. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available

  457. THOMAS JN, Roopkumar J, Patel T
    Machine learning analysis of volatolomic profiles in breath can identify non-invasive biomarkers of liver disease: A pilot study.
    PLoS One. 2021;16:e0260098.
    PubMed     Abstract available

  458. FRUNDT T, Kuballa L, Lutgehetman M, Norz D, et al
    Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.
    PLoS One. 2021;16:e0258450.
    PubMed     Abstract available

  459. YEN HH, Su PY, Huang SP, Wu L, et al
    Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    PLoS One. 2021;16:e0252286.
    PubMed     Abstract available

  460. CONGLY SE, Shaheen AA, Swain MG
    Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
    PLoS One. 2021;16:e0251741.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.